Second malignant neoplasms and cardiovascular disease following radiotherapy

Journal of the National Cancer Institute

Volumn 104, Issue 5, 2012, Pages 357-370

  Travis, Lois B ^a   Ng, Andrea K ^b,c   Allan, James M ^d   Pui, Ching Hon ^e,f   Kennedy, Ann R ^g   Xu, X George ^h   Purdy, James A ⁱ   Applegate, Kimberly ^j   Yahalom, Joachim ^k   Constine, Louis S ^a   Gilbert, Ethel S ^l   Boice, John D ^m,n  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^f UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h RENSSELAER POLYTECHNIC INSTITUTE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^l NATIONAL CANCER INSTITUTE   (United States)

^m VANDERBILT UNIVERSITY   (United States)

ⁿ INTERNATIONAL EPIDEMIOLOGY INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE OUTCOME; AGE DISTRIBUTION; ALCOHOL CONSUMPTION; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVOR; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHILDHOOD CANCER; CLINICAL EFFECTIVENESS; DIETARY INTAKE; DOSE RESPONSE; DOSIMETRY; ENERGY BALANCE; FOLLOW UP; GENETIC SUSCEPTIBILITY; GENOMICS; HUMAN; ONSET AGE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RACE DIFFERENCE; RADIATION DOSE; RADIOBIOLOGY; RISK ASSESSMENT; SECOND CANCER; SECOND MALIGNANT NEOPLASM; SEX DIFFERENCE; TOBACCO;

ADULT; AGE OF ONSET; ARRHYTHMIAS, CARDIAC; CARDIOVASCULAR DISEASES; CHILD; CONFOUNDING FACTORS (EPIDEMIOLOGY); DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEART BLOCK; HUMANS; INCIDENCE; MALE; MYOCARDIAL INFARCTION; NEOPLASMS; NEOPLASMS, RADIATION-INDUCED; NEOPLASMS, SECOND PRIMARY; POLYMORPHISM, GENETIC; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; RISK ASSESSMENT; RISK FACTORS; SEER PROGRAM; STROKE; SURVIVORS; UNITED STATES;

EID: 84863230431     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr533     Document Type: Article

References (202)

1. Altekruse SF, Kosary CL, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2007. http://seer.cancer.gov/csr/1975-2007/. Accessed October 4, 2010.
2. Ringborg U, Bergqvist D, Brorsson B, et al. The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of radiotherapy for cancer including a prospective survey of radiotherapy practice in Sweden 2001-summary and conclusions. Acta Oncol. 2003;42(5-6):357-365. (Pubitemid 37193830)
3. Ng AK, Bernardo MP, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol. 2002;20(8):2101-2108. (Pubitemid 34408801)
4. van den Belt-Dusebout AW, de Wit R, Gietema JA, et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol. 2007;25(28):4370-4378. (Pubitemid 350013842)
5. Travis LB, Beard C, Allan JM, et al. Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst. 2010;102(15):1114-1130.
6. Friedman DL, Whitton J, Leisenring W, et al. Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2010;102(14):1083-1095.
7. Travis LB, Bhatia S, Allan JM, et al. Management of adverse effects of treatment: second primary cancers. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, PA: Lippincott, Williams, and Wilkins; 2011;2393-2410.
8. Yahalom J, Portlock CS. Long-term cardiac and pulmonary complications of cancer therapy. Hematol Oncol Clin North Am. 2008;22(2):305-318, vii. (Pubitemid 351452100)
9. Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ. 2009;339:b4606.
10. NCI. Cancer Epidemiology Cohorts: Core Infrastructure and Methodological Research. http://epi.grants.cancer.gov/funding/cohorts/. Accessed September 28, 2010.
11. Robison LL, Armstrong GT, Boice JD, et al. The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research. J Clin Oncol. 2009;27(14):2308-2318.
12. Travis LB, Rabkin CS, Brown LM, et al. Cancer survivorship-genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst. 2006;98(1):15-25. (Pubitemid 43057089)
13. Bhatia S, Robison LL. Cancer survivorship research: opportunities and future needs for expanding the research base. Cancer Epidemiol Biomarkers Prev. 2008;17(7):1551-1557.
14. National Council on Radiation Protection and Measurements (NCRP) Scientific Committee 1-17. Second Primary Cancers and Cardiovascular Disease After Radiotherapy. NCRP Report No. 170. Bethesda, MD: National Council on Radiation Protection and Measurements.
15. Little JB. Radiation carcinogenesis. Carcinogenesis. 2000;21(3):397-404. (Pubitemid 30137925)
16. UNSCEAR. Non-Targeted and Delayed Effects of Exposure to Ionizing Radiation. Annex C. New York, NY: Annex C, United Nations. 2009.
17. Averbeck D. Does scientific evidence support a change from the LNT model for low-dose radiation risk extrapolation? Health Phys. 2009;97(5):493-504.
18. Kennedy AR. Factors that modify radiation-induced carcinogenesis. Health Phys. 2009;97(5):433-445.
19. Fry RJM, Ley RR. Ultraviolet radiation carcinogenesis. In: Slaga TJ, ed. Mechanisms of Tumor Promotion. Boca Raton, FL: CRC Press; 1984:73-96.
20. Burns FJ, Tang MS, Frenkel K, et al. Induction and prevention of carcinogenesis in rat skin exposed to space radiation. Radiat Environ Biophys. 2007;46(2):195-199. (Pubitemid 46726010)
21. Kennedy AR, Davis JG, Carlton W, et al. Effects of dietary antioxidant supplementation on the development of malignant lymphoma and other neoplastic lesions in mice exposed to proton or iron-ion radiation. Radiat Res. 2008;169(6):615-625. (Pubitemid 351793451)
22. Nutting C, Camplejohn RS, Gilchrist R, et al. A patient with 17 primary tumours and a germ line mutation in TP53: tumour induction by adjuvant therapy? Clin Oncol (R Coll Radiol). 2000;12(5):300-304.
23. Limacher JM, Frebourg T, Natarajan-Ame S, et al. Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int J Cancer. 2001;96(4):238-242. (Pubitemid 33081228)
24. Talwalkar SS, Yin CC, Naeem RC, et al. Myelodysplastic syndromes arising in patients with germline TP53 mutation and Li-Fraumeni syndrome. Arch Pathol Lab Med. 2010;134(7):1010-1015.
25. Sharif S, Ferner R, Birch JM, et al. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol. 2006;24(16):2570-2575. (Pubitemid 46630636)
26. Little MP, de Vathaire F, Shamsaldin A, et al. Risks of brain tumour following treatment for cancer in childhood: modification by genetic factors, radiotherapy and chemotherapy. Int J Cancer. 1998;78(3):269-275. (Pubitemid 28445359)
27. Wallin JL, Tanna N, Misra S, et al. Sinonasal carcinoma after irradiation for medulloblastoma in nevoid basal cell carcinoma syndrome. Am J Otolaryngol. 2007;28(5):360-362. (Pubitemid 47362446)
28. Bassal M, Mertens AC, Taylor L, et al. Risk of selected subsequent carcinomas in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2006;24(3):476-483. (Pubitemid 46630467)
29. Henderson TO, Whitton J, Stovall M, et al. Secondary sarcomas in childhood cancer survivors: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2007;99(4):300-308. (Pubitemid 47073493)
30. Breslow NE, Lange JM, Friedman DL, et al. Secondary malignant neoplasms after Wilms tumor: an international collaborative study. Int J Cancer. 2010;127(3):657-666.
31. Wong FL, Boice JD Jr., Abramson DH, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA. 1997;278(15):1262-1267. (Pubitemid 27435614)
32. Kleinerman RA, Tucker MA, Tarone RE, et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol. 2005;23(10):2272-2279. (Pubitemid 46218720)
33. Pazzaglia S, Mancuso M, Tanori M, et al. Modulation of patched-associated susceptibility to radiation induced tumorigenesis by genetic background. Cancer Res. 2004;64(11):3798-3806. (Pubitemid 38697288)
34. Pazzaglia S, Tanori M, Mancuso M, et al. Linking DNA damage to medulloblastoma tumorigenesis in patched heterozygous knockout mice. Oncogene. 2006;25(8):1165-1173.
35. Backlund MG, Trasti SL, Backlund DC, et al. Impact of ionizing radiation and genetic background on mammary tumorigenesis in p53-deficient mice. Cancer Res. 2001;61(17):6577-6582. (Pubitemid 32783267)
36. Chao RC, Pyzel U, Fridlyand J, et al. Therapy-induced malignant neoplasms in Nf1 mutant mice. Cancer Cell. 2005;8(4):337-348. (Pubitemid 41443418)
37. Bernstein JL, Haile RW, Stovall M, et al. Radiation exposure, the ATM Gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study. J Natl Cancer Inst. 2010;102(7):475-483.
38. Graeser MK, Engel C, Rhiem K, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2009;27(35):5887-5892.
39. Nichols KE, Levitz S, Shannon KE, et al. Heterozygous germline ATM mutations do not contribute to radiation-associated malignancies after Hodgkin's disease. J Clin Oncol. 1999;17(4):1259.
40. Offit K, Gilad S, Paglin S, et al. Rare variants of ATM and risk for Hodgkin's disease and radiation-associated breast cancers. Clin Cancer Res. 2002;8(12):3813-3819. (Pubitemid 35424774)
41. Narod SA, Lubinski J, Ghadirian P, et al. Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet Oncol. 2006;7(5):402-406.
42. Andrieu N, Easton DF, Chang-Claude J, et al. Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group. J Clin Oncol. 2006;24(21):3361-3366. (Pubitemid 46638890)
43. Berrington de Gonzalez A, Berg CD, Visvanathan K, et al. Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers. J Natl Cancer Inst. 2009;101(3):205-209.
44. Li X, Dumont P, Della Pietra A, et al. The codon 47 polymorphism in p53 is functionally significant. J Biol Chem. 2005;280(25):24245-24251. (Pubitemid 40884914)
45. Angele S, Romestaing P, Moullan N, et al. ATM haplotypes and cellular response to DNA damage: association with breast cancer risk and clinical radiosensitivity. Cancer Res. 2003;63(24):8717-8725. (Pubitemid 38064049)
46. Gutierrez-Enriquez S, Fernet M, Dork T, et al. Functional consequences of ATM sequence variants for chromosomal radiosensitivity. Genes Chromosomes Cancer. 2004;40(2):109-119. (Pubitemid 38579879)
47. Zhu F, Dolle ME, Berton TR. Mouse models for the p53 R72P polymorphism mimic human phenotypes. Cancer Res. 2010;70(14):5851-5859.
48. Rajaraman P, Bhatti P, Doody MM, et al. Nucleotide excision repair polymorphisms may modify ionizing radiation-related breast cancer risk in US radiologic technologists. Int J Cancer. 2008;123(11):2713-2716.
49. Schonfeld SJ, Bhatti P, Brown EE, et al. Polymorphisms in oxidative stress and inflammation pathway genes, low-dose ionizing radiation, and the risk of breast cancer among US radiologic technologists. Cancer Causes Control. 2010;21(11):1857-1866.
50. Sigurdson AJ, Bhatti P, Chang SC, et al. Polymorphisms in estrogen biosynthesis and metabolism-related genes, ionizing radiation exposure, and risk of breast cancer among US radiologic technologists. Breast Cancer Res Treat. 2009;118(1):177-184.
51. Sigurdson AJ, Bhatti P, Doody MM, et al. Polymorphisms in apoptosis-and proliferation-related genes, ionizing radiation exposure, and risk of breast cancer among U.S. Radiologic Technologists. Cancer Epidemiol Biomarkers Prev. 2007;16(10):2000-2007. (Pubitemid 47621173)
52. Bhatti P, Struewing JP, Alexander BH, et al. Polymorphisms in DNA repair genes, ionizing radiation exposure and risk of breast cancer in U.S. Radiologic technologists. Int J Cancer. 2008;122(1):177-182. (Pubitemid 350209993)
53. Bhatti P, Doody MM, Rajaraman P, et al. Novel breast cancer risk alleles and interaction with ionizing radiation among U.S. radiologic technologists. Radiat Res. 2010;173(2):214-224.
54. Bhatti P, Doody MM, Alexander BH, et al. Breast cancer risk polymorphisms and interaction with ionizing radiation among U.S. radiologic technologists. Cancer Epidemiol Biomarkers Prev. 2008;17(8):2007-2011.
55. Lonn S, Bhatti P, Alexander BH, et al. Papillary thyroid cancer and polymorphic variants in TSHR-and RET-related genes: a nested case-control study within a cohort of U.S. radiologic technologists. Cancer Epidemiol Biomarkers Prev. 2007;16(1):174-177. (Pubitemid 46174283)
56. Chang-Claude J, Ambrosone CB, Lilla C, et al. Genetic polymorphisms in DNA repair and damage response genes and late normal tissue complications of radiotherapy for breast cancer. Br J Cancer. 2009;100(10):1680-1686.
57. Chang-Claude J, Popanda O, Tan XL, et al. Association between polymorphisms in the DNA repair genes, XRCC1, APE1, and XPD and acute side effects of radiotherapy in breast cancer patients. Clin Cancer Res. 2005;11(13):4802-4809. (Pubitemid 41557201)
58. Tan XL, Popanda O, Ambrosone CB, et al. Association between TP53 and p21 genetic polymorphisms and acute side effects of radiotherapy in breast cancer patients. Breast Cancer Res Treat. 2006;97(3):255-262. (Pubitemid 43945755)
59. De Ruyck K, Van Eijkeren M, Claes K, et al. TGFbeta1 polymorphisms and late clinical radiosensitivity in patients treated for gynecologic tumors. Int J Radiat Oncol Biol Phys. 2006;65(4):1240-1248.
60. Werbrouck J, De Ruyck K, Duprez F, et al. Acute normal tissue reactions in head-and-neck cancer patients treated with IMRT: influence of dose and association with genetic polymorphisms in DNA DSB repair genes. Int J Radiat Oncol Biol Phys. 2009;73(4):1187-1195.
61. Azria D, Ozsahin M, Kramar A, et al. Single nucleotide polymorphisms, apoptosis, and the development of severe late adverse effects after radiotherapy. Clin Cancer Res. 2008;14(19):6284-6288.
62. Burri RJ, Stock RG, Cesaretti JA, et al. Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer. Radiat Res. 2008;170(1):49-59. (Pubitemid 351931187)
63. Kuptsova N, Chang-Claude J, Kropp S, et al. Genetic predictors of long-term toxicities after radiation therapy for breast cancer. Int J Cancer. 2008;122(6):1333-1339. (Pubitemid 351287234)
64. Yoshida K, Nakachi K, Imai K, et al. Lung cancer susceptibility among atomic bomb survivors in relation to CA repeat number polymorphism of epidermal growth factor receptor gene and radiation dose. Carcinogenesis. 2009;30(12):2037-2041.
65. Pugh TJ, Keyes M, Barclay L, et al. Sequence variant discovery in DNA repair genes from radiosensitive and radiotolerant prostate brachytherapy patients. Clin Cancer Res. 2009;15(15):5008-5016.
66. Sigurdson AJ, Land CE, Bhatti P, et al. Thyroid nodules, polymorphic variants in DNA repair and RET-related genes, and interaction with ionizing radiation exposure from nuclear tests in Kazakhstan. Radiat Res. 2009;171(1):77-88.
67. Zhang L, Yang M, Bi N, et al. ATM polymorphisms are associated with risk of radiation-induced pneumonitis. Int J Radiat Oncol Biol Phys. 2010;77(5):1360-1368.
68. Zheng YL, Kosti O, Loffredo CA, et al. Elevated lung cancer risk is associated with deficiencies in cell cycle checkpoints: genotype and phenotype analyses from a case-control study. Int J Cancer. 2010;126(9):2199-2210.
69. Knight JA, Skol AD, Shinde A, et al. Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility. Blood. 2009;113(22):5575-5582.
70. Ingle JN, Schaid DJ, Goss PE, et al. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol. 2010;28(31):4674-4682.
71. Best T, Li D, Skol AD, et al. Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma. Nat Med. 2011;17(8):941-943.
72. Cirulli ET, Goldstein DB. Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat Rev Genet. 2010;11(6):415-425.
73. West C, Rosenstein BS, Alsner J. Establishment of a Radiogenomics Consortium. Int J Radiat Oncol Biol Phys. 2010;76(5):1295-1296.
74. Wu X, Spitz MR, Lee JJ, et al. Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev Res (Phila). 2009;2(7):617-624.
75. Travis LB, Hill D, Dores GM, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst. 2005;97(19):1428-1437. (Pubitemid 41520078)
76. Longo DL. Radiation therapy in Hodgkin disease: why risk a Pyrrhic victory? J Natl Cancer Inst. 2005;97(19):1394-1395.
77. Hindorff LA, Sethupathy P, Junkins HA, et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci USA. 2009;106(23):9362-9367.
78. NHGRI. A Catalog of Published Genome-Wide Association Studies. http://www.genome.gov/26525384. Accessed March 29, 2010.
79. Hirsch HA, Iliopoulos D, Joshi A, et al. A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases. Cancer Cell. 2010;17(4):348-361.
80. Wethal T, Haugnes HS, Kjekshus J, et al. C-reactive protein; a potential marker of second cancer and cardiovascular disease in testicular cancer survivors? Eur J Cancer. 2010;46(18):3425-3433.
81. Purdy JA. From new frontiers to new standards of practice: advances in radiotherapy planning and delivery. In: Meyer JL, ed. IMRT, IGRT, SBRT-Advances in the Treatment Planning and Delivery of Radiotherapy. Basel, Switzerland: Karger; 2007:18-39.
82. Intensity Modulated Radiation Therapy Collaborative Working Group. Intensity-modulated radiotherapy: current status and issues of interest. Int J Radiat Oncol Biol Phys. 2001;51(4):880-914.
83. Leksell L. The stereotaxic method and radiosurgery of the brain. Acta Chir Scand. 1951;102(4):316-319.
84. Leksell L. Cerebral radiosurgery. I. Gammathalanotomy in two cases of intractable pain. Acta Chir Scand. 1968;134(8):585-595.
85. Lutz W, Winston KR, Maleki N. A system for stereotactic radiosurgery with a linear accelerator. Int J Radiat Oncol Biol Phys. 1988;14(2):373-381. (Pubitemid 18042200)
86. Brown JR, Yeckes H, Friedberg JW, et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 2005;23(10):2208-2214. (Pubitemid 46218712)
87. Delaney TF, Kooy HM. Proton and Charged Particle Radiotherapy. Philadelphia, PA: Lippincott, Williams, and Wilkins; 2008.
88. Bortfeld T, Schmidt-Ullrich R, De Neve W, et al. Image-Guided IMRT. Berlin, Germany: Springer; 2005.
89. Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys. 2006;65(1):1-7.
90. Hodgson DC, Gilbert ES, Dores GM, et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol. 2007;25(12):1489- 1497. (Pubitemid 46759253)
91. Purdy JA. Dose to normal tissues outside the radiation therapy patient's treated volume: a review of different radiation therapy techniques. Health Phys. 2008;95(5):666-676.
92. Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA. 2003;290(4):465-475. (Pubitemid 37430500)
93. van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst. 2003;95(13):971-980. (Pubitemid 36896714)
94. Ng AK, Bernardo MV, Weller E, et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood. 2002;100(6):1989-1996. (Pubitemid 35001228)
95. De Bruin ML, Sparidans J, van't Veer MB, et al. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. J Clin Oncol. 2009;27(26):4239-4246.
96. Basu SK, Schwartz C, Fisher SG, et al. Unilateral and bilateral breast cancer in women surviving pediatric Hodgkin's disease. Int J Radiat Oncol Biol Phys. 2008;72(1):34-40.
97. Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst. 2002;94(3):182-192. (Pubitemid 34162752)
98. Swerdlow AJ, Schoemaker MJ, Allerton R, et al. Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. J Clin Oncol. 2001;19(6):1610-1618. (Pubitemid 32230860)
99. O'Brien MM, Donaldson SS, Balise RR, et al. Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy. J Clin Oncol. 2010;28(7):1232-1239.
100. Stovall M, Smith SA, Langholz BM, et al. Dose to the contralateral breast from radiotherapy and risk of second primary breast cancer in the WECARE study. Int J Radiat Oncol Biol Phys. 2008;72(4):1021-1030.
101. van den Belt-Dusebout AW, Aleman BM, Besseling G, et al. Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy. Int J Radiat Oncol Biol Phys. 2009;75(5):1420-1429.
102. Mauch P, Ng A, Aleman B, et al. Report from the Rockefellar Foundation Sponsored International Workshop on reducing mortality and improving quality of life in long-term survivors of Hodgkin's disease: July 9-16, 2003, Bellagio, Italy. Eur J Haematol Suppl. 2005;(66):68-76. (Pubitemid 40873981)
103. van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. J Natl Cancer Inst. 1995;87(20):1530-1537.
104. Dores GM, Cote TR, Travis LB. New malignancies following Hodgkin lymphoma, non-Hodgkin lymphoma, and myeloma. In. New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. Bethesda, MD: National Cancer Institute; 2006; NIH Pub No. 05-5302.
105. Mudie NY, Swerdlow AJ, Higgins CD, et al. Risk of second malignancy after non-Hodgkin's lymphoma: a British Cohort Study. J Clin Oncol. 2006;24(10):1568-1574. (Pubitemid 46638780)
106. Sacchi S, Marcheselli L, Bari A, et al. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. Haematologica. 2008;93(3):398-404. (Pubitemid 351398641)
107. Tward JD, Wendland MM, Shrieve DC, et al. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer. 2006;107(1):108-115. (Pubitemid 43939037)
108. Landgren O, Pfeiffer RM, Stewart L, et al. Risk of second malignant neoplasms among lymphoma patients with a family history of cancer. Int J Cancer. 2007;120(5):1099-1102. (Pubitemid 46214312)
109. Travis LB, Weeks J, Curtis RE, et al. Leukemia following low-dose total body irradiation and chemotherapy for non-Hodgkin's lymphoma. J Clin Oncol. 1996;14(2):565-571. (Pubitemid 26051022)
110. Travis LB, Curtis RE, Glimelius B, et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst. 1995;87(7):524-530.
111. Travis LB, Curtis RE, Stovall M, et al. Risk of leukemia following treatment for non-Hodgkin's lymphoma. J Natl Cancer Inst. 1994;86(19):1450-1457. (Pubitemid 24317586)
112. Travis LB, Curtis RE, Glimelius B, et al. Second cancers among long-term survivors of non-Hodgkin's lymphoma. J Natl Cancer Inst. 1993;85(23):1932-1937. (Pubitemid 23354032)
113. Travis LB, Holowaty E, Hunter V, et al. Acute basophilic leukemia and acute eosinophilic leukemia after therapy for non-Hodgkin's lymphoma. Am J Clin Pathol. 1993;100(2):186. (Pubitemid 23251890)
114. Travis LB, Gonzalez CL, Hankey BF, et al. Hodgkin's disease following non-Hodgkin's lymphoma. Cancer. 1992;69(9):2337-2342.
115. Travis LB, Curtis RE, Boice JD Jr., et al. Second cancers following non-Hodgkin's lymphoma. Cancer. 1991;67(7):2002-2009.
116. Greene MH, Young RC, Merrill JM, et al. Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma. Cancer Res. 1983;43(4):1891-1898. (Pubitemid 13122600)
117. Teta MJ, Lau E, Sceurman BK, et al. Therapeutic radiation for lymphoma: risk of malignant mesothelioma. Cancer. 2007;109(7):1432-1438. (Pubitemid 46466572)
118. Pedersen-Bjergaard J, Andersen MK, Christiansen DH. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood. 2000;95(11):3273-3279. (Pubitemid 30428453)
119. Hosing C, Munsell M, Yazji S, et al. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. Ann Oncol. 2002;13(3):450-459. (Pubitemid 34705008)
120. Metayer C, Curtis RE, Vose J, et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood. 2003;101(5):2015-2023. (Pubitemid 36237609)
121. Friedman DL, Rovo A, Leisenring W, et al. Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party. Blood. 2008;111(2):939-944.
122. Rizzo JD, Curtis RE, Socie G, et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood. 2009;113(5):1175-1183.
123. Travis LB, Andersson M, Gospodarowicz M, et al. Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst. 2000;92(14):1165-1171.
124. Travis LB, Fossa SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst. 2005;97(18):1354-1365. (Pubitemid 41487803)
125. Chung P, Mayhew LA, Warde P, et al. Management of stage I seminomatous testicular cancer: a systematic review. Clin Oncol (R Coll Radiol). 2010;22(1):6-16.
126. Kirova YM, Gambotti L, De Rycke Y, et al. Risk of second malignancies after adjuvant radiotherapy for breast cancer: a large-scale, single-institution review. Int J Radiat Oncol Biol Phys. 2007;68(2):359-363. (Pubitemid 46694165)
127. Hemminki K, Ji J, Forsti A. Risks for familial and contralateral breast cancer interact multiplicatively and cause a high risk. Cancer Res. 2007;67(3):868-870.
128. Boice JD Jr, Harvey EB, Blettner M, et al. Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med. 1992;326(12):781-785.
129. Hooning MJ, Aleman BM, Hauptmann M, et al. Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer. J Clin Oncol. 2008;26(34):5561-5568.
130. Zablotska LB, Neugut AI. Lung carcinoma after radiation therapy in women treated with lumpectomy or mastectomy for primary breast carcinoma. Cancer. 2003;97(6):1404-1411. (Pubitemid 36297769)
131. Deutsch M, Land SR, Begovic M, et al. The incidence of lung carcinoma after surgery for breast carcinoma with and without postoperative radiotherapy. Results of National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials B-04 and B-06. Cancer. 2003;98(7):1362-1368. (Pubitemid 37151489)
132. Kaufman EL, Jacobson JS, Hershman DL, et al. Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. J Clin Oncol. 2008;26(3):392-398. (Pubitemid 351171690)
133. Zablotska LB, Chak A, Das A, et al. Increased risk of squamous cell esophageal cancer after adjuvant radiation therapy for primary breast cancer. Am J Epidemiol. 2005;161(4):330-337. (Pubitemid 40256204)
134. Kirova YM, Vilcoq JR, Asselain B, et al. Radiation-induced sarcomas after radiotherapy for breast carcinoma: a large-scale single-institution review. Cancer. 2005;104(4):856-863. (Pubitemid 41113688)
135. Kleinerman RA, Curtis RE, Boice JD Jr, et al. Second cancers following radiotherapy for cervical cancer. J Natl Cancer Inst. 1982;69(5):1027-1033. (Pubitemid 13254891)
136. Kleinerman RA, Boice JD Jr, Storm HH, et al. Second primary cancer after treatment for cervical cancer. An international cancer registries study. Cancer. 1995;76(3):442-452.
137. Boice JD Jr, Engholm G, Kleinerman RA, et al. Radiation dose and second cancer risk in patients treated for cancer of the cervix. Radiat Res. 1988;116(1):3-55.
138. Boice JD Jr, Blettner M, Kleinerman RA, et al. Radiation dose and leukemia risk in patients treated for cancer of the cervix. J Natl Cancer Inst. 1987;79(6):1295-1311. (Pubitemid 18036735)
139. Chaturvedi AK, Engels EA, Gilbert ES. Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst. 2007;99(21):1634-1643.
140. Pickles T, Phillips N. The risk of second malignancy in men with prostate cancer treated with or without radiation in British Columbia, 1984-2000. Radiother Oncol. 2002;65(3):145-151. (Pubitemid 35441045)
141. Moon K, Stukenborg GJ, Keim J, et al. Cancer incidence after localized therapy for prostate cancer. Cancer. 2006;107(5):991-998. (Pubitemid 44291148)
142. Brenner DJ, Curtis RE, Hall EJ, et al. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer. 2000;88(2):398-406. (Pubitemid 30051826)
143. Abdel-Wahab M, Reis IM, Wu J, et al. Second primary cancer risk of radiation therapy after radical prostatectomy for prostate cancer: an analysis of SEER data. Urology. 2009;74(4):866-871.
144. Kendal WS, Eapen L, Macrae R, et al. Prostatic irradiation is not associated with any measurable increase in the risk of subsequent rectal cancer. Int J Radiat Oncol Biol Phys. 2006;65(3):661-668. (Pubitemid 43795833)
145. Chrouser K, Leibovich B, Bergstralh E, et al. Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer. J Urol. 2005;174(1):107-110; discussion 110-111. (Pubitemid 40825684)
146. Movsas B, Hanlon AL, Pinover W, et al. Is there an increased risk of second primaries following prostate irradiation? Int J Radiat Oncol Biol Phys. 1998;41(2):251-255. (Pubitemid 28243533)
147. Armstrong GT, Liu W, Leisenring W, et al. Occurrence of multiple subsequent neoplasms in long-term survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol. 2011;29(22):3056-3064.
148. Tukenova M, Guibout C, Hawkins M, et al. Radiation therapy and late mortality from second sarcoma, carcinoma, and hematological malignancies after a solid cancer in childhood. Int J Radiat Oncol Biol Phys. 2011;80(2):339-346.
149. Castellino SM, Geiger AM, Mertens AC, et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood. 2011;117(6):1806-1816.
150. Bhatia S, Sather HN, Pabustan OB, et al. Low incidence of second neoplasms among children diagnosed with acute lymphoblastic leukemia after 1983. Blood. 2002;99(12):4257-4264. (Pubitemid 34627190)
151. Loning L, Zimmermann M, Reiter A, et al. Secondary neoplasms subsequent to Berlin-Frankfurt-Munster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. Blood. 2000;95(9):2770-2775. (Pubitemid 30235882)
152. Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst. 2001;93(8):618-629. (Pubitemid 32409629)
153. Pui CH, Cheng C, Leung W, et al. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med. 2003;349(7):640-649. (Pubitemid 36975996)
154. Hijiya N, Hudson MM, Lensing S, et al. Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA. 2007;297(11):1207-1215. (Pubitemid 46465729)
155. Leung W, Ribeiro RC, Hudson M, et al. Second malignancy after treatment of childhood acute myeloid leukemia. Leukemia. 2001;15(1):41-45. (Pubitemid 32124066)
156. Goshen Y, Stark B, Kornreich L, et al. High incidence of meningioma in cranial irradiated survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer,. 2007;49(3):294-297. (Pubitemid 47236219)
157. Neglia JP, Robison LL, Stovall M, et al. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2006;98(21):1528-1537. (Pubitemid 44680904)
158. Walter AW, Hancock ML, Pui CH, et al. Secondary brain tumors in children treated for acute lymphoblastic leukemia at St Jude Children's Research Hospital. J Clin Oncol. 1998;16(12):3761-3767. (Pubitemid 29001527)
159. Relling MV, Rubnitz JE, Rivera GK, et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet. 1999;354(9172):34-39. (Pubitemid 29304300)
160. Ergun-Longmire B, Mertens AC, Mitby P, et al. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab. 2006;91(9):3494-3498. (Pubitemid 44402126)
161. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood. 2000;95(11):3310-3322. (Pubitemid 30428458)
162. Pui CH, Carroll WL, Meshinci S, et al. Biology, risk stratification and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011;29(5):551-565.
163. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360(26):2730-2741.
164. Kamps WA, van der Pal-de Bruin KM, Veerman AJ, et al. Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004. Leukemia. 2010;24(2):309-319.
165. Inskip PD, Robison LL, Stovall M, et al. Radiation dose and breast cancer risk in the childhood cancer survivor study. J Clin Oncol. 2009;27(24):3901- 3907.
166. Sigurdson AJ, Ronckers CM, Mertens AC, et al. Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case-control study. Lancet. 2005;365(9476):2014-2023. (Pubitemid 40805009)
167. Curtis RE, Boice JD Jr, Stovall M, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med. 1992;326(26):1745-1751.
168. Curtis RE, Boice JD Jr, Stovall M, et al. Relationship of leukemia risk to radiation dose following cancer of the uterine corpus. J Natl Cancer Inst. 1994;86(17):1315-1324. (Pubitemid 24276793)
169. Gilbert ES, Stovall M, Gospodarowicz M, et al. Lung cancer after treatment for Hodgkin's disease: focus on radiation effects. Radiat Res. 2003;159(2):161-173. (Pubitemid 36182394)
170. Kaldor JM, Day NE, Clarke EA, et al. Leukemia following Hodgkin's disease. N Engl J Med. 1990;322(1):7-13. (Pubitemid 20023826)
171. Tucker MA, D'Angio GJ, Boice JD Jr, et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med. 1987;317(10):588-593. (Pubitemid 17126781)
172. Swerdlow AJ, Barber JA, Hudson GV, et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol. 2000;18(3):498-509. (Pubitemid 30078531)
173. Reulen RC, Winter DL, Frobisher C, et al. Long-term cause-specific mortality among survivors of childhood cancer. JAMA. 2010;304(2):172-179.
174. Applefeld MM, Cole JF, Pollock SH, et al. The late appearance of chronic pericardial disease in patients treated by radiotherapy for Hodgkin's disease. Ann Intern Med. 1981;94(3):338-341. (Pubitemid 11137073)
175. Ling LH, Oh JK, Schaff HV, et al. Constrictive pericarditis in the modern era: evolving clinical spectrum and impact on outcome after pericardiectomy. Circulation. 1999;100(13):1380-1386. (Pubitemid 29451696)
176. Stewart JR, Fajardo LF, Gillette SM, et al. Radiation injury to the heart. Int J Radiat Oncol Biol Phys. 1995;31(5):1205-1211.
177. Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol. 1993;11(7):1208-1215. (Pubitemid 23199121)
178. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109(5):1878- 1886. (Pubitemid 46348183)
179. Heidenreich PA, Hancock SL, Vagelos RH, et al. Diastolic dysfunction after mediastinal irradiation. Am Heart J. 2005;150(5):977-982. (Pubitemid 41607777)
180. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA. 1993;270(16):1949- 1955. (Pubitemid 23312611)
181. Borger JH, Hooning MJ, Boersma LJ, et al. Cardiotoxic effects of tangential breast irradiation in early breast cancer patients: the role of irradiated heart volume. Int J Radiat Oncol Biol Phys. 2007;69(4):1131-1138. (Pubitemid 47625827)
182. Correa CR, Litt HI, Hwang WT, et al. Coronary artery findings after left-sided compared with right-sided radiation treatment for early-stage breast cancer. J Clin Oncol. 2007;25(21):3031-3037. (Pubitemid 47218049)
183. Hojris I, Overgaard M, Christensen JJ, et al. Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials. Radiotherapy Committee of the Danish Breast Cancer Cooperative Group. Lancet. 1999;354(9188):1425-1430. (Pubitemid 29494754)
184. Hooning MJ, Botma A, Aleman BM, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst. 2007;99(5):365-375. (Pubitemid 47073480)
185. Paszat LF, Vallis KA, Benk VM, et al. A population-based case-cohort study of the risk of myocardial infarction following radiation therapy for breast cancer. Radiother Oncol. 2007;82(3):294-300. (Pubitemid 46341476)
186. Vallis KA, Pintilie M, Chong N, et al. Assessment of coronary heart disease morbidity and mortality after radiation therapy for early breast cancer. J Clin Oncol. 2002;20(4):1036-1042. (Pubitemid 34141848)
187. Hill-Kayser CE, Harris EE, Hwang WT, et al. Twenty-year incidence and patterns of contralateral breast cancer after breast conservation treatment with radiation. Int J Radiat Oncol Biol Phys. 2006;66(5):1313-1319.
188. Harris EE, Correa C, Hwang WT, et al. Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. J Clin Oncol. 2006;24(25):4100-4106. (Pubitemid 46622285)
189. Carlson RG, Mayfield WR, Normann S, et al. Radiation-associated valvular disease. Chest. 1991;99(3):538-545.
190. Tamura A, Takahara Y, Mogi K, et al. Radiation-induced valvular disease is the logical consequence of irradiation. Gen Thorac Cardiovasc Surg. 2007;55(2):53-56. (Pubitemid 46465374)
191. Hull MC, Morris CG, Pepine CJ, et al. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA. 2003;290(21):2831-2837. (Pubitemid 37509491)
192. Orzan F, Brusca A, Gaita F, et al. Associated cardiac lesions in patients with radiation-induced complete heart block. Int J Cardiol. 1993;39(2):151-156. (Pubitemid 23162756)
193. Adams MJ, Lipsitz SR, Colan SD, et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol. 2004;22(15):3139-3148. (Pubitemid 41103728)
194. Glanzmann C, Kaufmann P, Jenni R, et al. Cardiac risk after mediastinal irradiation for Hodgkin's disease. Radiother Oncol. 1998;46(1):51-62. (Pubitemid 28072859)
195. Cameron EH, Lipshultz SE, Tarbell NJ, et al. Cardiovascular disease in long-term survivors of pediatric Hodgkin's disease. Prog Pediatr Cardiol. 1998;8:139-144. (Pubitemid 28200699)
196. Tolba KA, Deliargyris EN. Cardiotoxicity of cancer therapy. Cancer Invest. 1999;17(6):408-422. (Pubitemid 29359888)
197. Marks LB, Yu X, Prosnitz RG, et al. The incidence and functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys. 2005;63(1):214-223. (Pubitemid 41583561)
198. Schellong G, Riepenhausen M, Bruch C, et al. Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. Pediatr Blood Cancer. 2010;55(6):1145-1152.
199. Scott AS, Parr LA, Johnstone PA. Risk of cerebrovascular events after neck and supraclavicular radiotherapy: a systematic review. Radiother Oncol. 2009;90(2):163-165.
200. Smith GL, Smith BD, Buchholz TA, et al. Cerebrovascular disease risk in older head and neck cancer patients after radiotherapy. J Clin Oncol. 2008;26(31):5119-5125.
201. De Bruin ML, Dorresteijn LD, van't Veer MB, et al. Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst. 2009;101(13):928-937.
202. Bowers DC, Liu Y, Leisenring W, et al. Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2006;24(33):5277-5282. (Pubitemid 46631374)